Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

Mulhollandr Jul. 11 at 7:58 PM

$CLNN hmmm…really want to add to my position…maybe it’ll dip a bit lower. 🤞🏼

0 · Reply

Impatient_Investor Jul. 10 at 6:16 PM

$CLNN Most of the analysts are corrupt as they do what institutional investors tell them to do so.

0 · Reply

bullyboybilll Jul. 9 at 7:31 PM

$CLNN ok about this 🐢 here Featured Analyst Highlights Jason Kolbert (D. Boral Capital) maintains a Buy rating with a $23 target (~+500% upside) as of June 30, 2025 Yahoo Finance+9Stock Analysis+9AnaChart+9. Bruce Jackson (Benchmark) continues his Strong Buy, recently lowering target to $33 (~+700%) Nasdaq+5Stock Analysis+5Ticker Nerd+5. Joseph Pantginis (HC Wainwright) reiterates Buy with a $31 target (~+700%) Fintel+4Stock Analysis+4Ticker Nerd+4. Justin Walsh (Jones Trading) initiated coverage with Buy, $30 target (~+680%) Ticker Nerd+2Stock Analysis+2MarketBeat+2.

0 · Reply

GreenResearchers Jul. 9 at 6:10 PM

ATER is stupid undervalued. Millions in annual sales. Real products. Improving margins. 100% short utilization and a chart that looks coiled under $2. This is the kind of setup that erupts when the pressure finally releases just like $SGMA did. $TRKA $CLNN $HUBC

0 · Reply

bullyboybilll Jul. 9 at 1:22 PM

$PCSA fda approval 🐢 $1.50+ $HOLO $MLGO $CLNN

0 · Reply

NetworkNewsWire Jul. 8 at 7:12 PM

Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice $CLNN https://ibn.fm/mnCHy #biomedstocks #Parkinson’s

0 · Reply

UniversalTrading Jul. 8 at 11:45 AM

$CLNN Has anyone else seen or heard the whispers on the new Reddit vLog regarding a Clene Buyout? Apparently big News / PR is landing today .. !! GLTA!

1 · Reply

UniversalTrading Jul. 8 at 10:56 AM

$CLNN Look at the ASC Scale to Ratio Chart on $ CLNN now .. it looks insane. And that is live, real-time, factual data. Ignore all the Noise and negativity .. Traders simply trying to drive the SP down. Literally Buy all you can and or Hold on these Dips. Something positive is definitely bubbling here. Mark it!!

0 · Reply

NetworkNewsWire Jul. 7 at 7:26 PM

$CLNN to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025 https://ibn.fm/o1QjE

0 · Reply

Impatient_Investor Jul. 7 at 5:36 PM

$CLNN why institutional investors are not interested as their holding is at all time low. May be they know what's going to happen with this garbage

0 · Reply

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 4 weeks ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 2 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 14, 2025, 8:30 AM EDT - 3 months ago

Clene to Present at the Emerging Growth Conference

Apr 1, 2025, 8:30 AM EDT - 3 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 3 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 4 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 4 months ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 4 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 4 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 7 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 10 months ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 10 months ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 11 months ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 1 year ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 1 year ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 1 year ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 1 year ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 7:00 AM EDT - 1 year ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Pricing of $40 Million Public Offering

Jun 15, 2023, 4:38 PM EDT - 2 years ago

Clene Announces Launch of Proposed Public Offering

Jun 15, 2023, 4:29 PM EDT - 2 years ago

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Jun 15, 2023, 7:00 AM EDT - 2 years ago

Clene to Participate in the Maxim Group Virtual Healthcare Conference

May 12, 2023, 4:00 PM EDT - 2 years ago

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

Apr 25, 2023, 4:05 PM EDT - 2 years ago

ALS and MS Clinical Data from Clene's CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

Apr 11, 2023, 8:00 AM EDT - 2 years ago

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

Mulhollandr Jul. 11 at 7:58 PM

$CLNN hmmm…really want to add to my position…maybe it’ll dip a bit lower. 🤞🏼

0 · Reply

Impatient_Investor Jul. 10 at 6:16 PM

$CLNN Most of the analysts are corrupt as they do what institutional investors tell them to do so.

0 · Reply

bullyboybilll Jul. 9 at 7:31 PM

0 · Reply

GreenResearchers Jul. 9 at 6:10 PM

0 · Reply

bullyboybilll Jul. 9 at 1:22 PM

$PCSA fda approval 🐢 $1.50+ $HOLO $MLGO $CLNN

0 · Reply

NetworkNewsWire Jul. 8 at 7:12 PM

Preclinical Study Finds a Way to Reverse Symptoms of Parkinson’s in Mice $CLNN https://ibn.fm/mnCHy #biomedstocks #Parkinson’s

0 · Reply

UniversalTrading Jul. 8 at 11:45 AM

$CLNN Has anyone else seen or heard the whispers on the new Reddit vLog regarding a Clene Buyout? Apparently big News / PR is landing today .. !! GLTA!

1 · Reply

UniversalTrading Jul. 8 at 10:56 AM

0 · Reply

NetworkNewsWire Jul. 7 at 7:26 PM

$CLNN to Conduct Neurofilament Biomarker Analysis for CNM-Au8(R) in ALS in Early Q4 2025 https://ibn.fm/o1QjE

0 · Reply

Impatient_Investor Jul. 7 at 5:36 PM

$CLNN why institutional investors are not interested as their holding is at all time low. May be they know what's going to happen with this garbage

0 · Reply

ransoms21212 Jul. 7 at 4:54 PM

$CLNN new HC report following CLNN earnings

1 · Reply

Impatient_Investor Jul. 7 at 8:44 AM

$CLNN why only retailers are bullish not institutional investors?

2 · Reply

Impatient_Investor Jul. 6 at 7:23 AM

$CLNN

0 · Reply

ransoms21212 Jul. 4 at 6:12 PM

$CLNN TBH if the company can raise enough with the ATM to get thru finish line, that may be most favorable outcome...price needs market support for this to be viable though...going to step up purchases with ATM

0 · Reply

Rage_Against_The_Machine Jul. 3 at 8:38 PM

Clene ($CLNN) taps markets again - files for $2M stock sale after burning through 83% of cash reserves in 9 months. Dilution becomes the new core competency while waiting for FDA salvation. Investors: check your share count... again. https://www.sec.gov/Archives/edgar/data/1822791/000143774925022150/clnn20250702_8k.htm

1 · Reply

Ravery Jul. 3 at 11:45 AM

$CLNN The share price will likely continue to have a lid on it until their is clarity on how the cash runway will be extended. Despite the fact that short interest is at a 52 week high, it still sits at 355K, which is minimal, so no short squeeze opportunity. The science is too good here for such a small enterprise value. IF they find a way to rectify the balance sheet without devastating dilution, I would expect the price to readjust much higher. GL longs.

1 · Reply

Impatient_Investor Jul. 3 at 9:47 AM

$CLNN

1 · Reply

Impatient_Investor Jul. 3 at 9:33 AM

$CLNN

0 · Reply

Impatient_Investor Jul. 3 at 9:33 AM

$CLNN tomorrow i am going to sell this garbage and reopen after a month or two.

2 · Reply

Impatient_Investor Jul. 2 at 3:45 PM

$CLNN it looks like only retailers are bullish not the highly experienced hedge funds and institutional investors. Do retailers know better?

1 · Reply

bullyboybilll Jul. 1 at 10:46 PM

$CLNN oh this 🐢 🔥 Any Reason for Doubt? Minimal: With two additional Type C and B meetings already scheduled and active signals of acceptance of their SAP, the process is clearly progressing — not stalled or at risk. Key jockeying factor: The only remaining hurdle is final SAP acceptance, expected this summer — and the FDA responded with constructive feedback, not rejection. Bullish AFter hours 🗣

3 · Reply

Impatient_Investor Jul. 1 at 5:35 PM

$CLNN its time for dilution. Sell and reenter.

0 · Reply

Market Cap	29.68M
Revenue (ttm)	340,000.00
Net Income (ttm)	-39.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,588.24%
Debt to Equity Ratio	-0.39

Volume	75,000
Avg Vol	94,714
Day's Range	N/A - N/A
Shares Out	8.27M
Stochastic %K	9%
Beta	0.55
Analysts	Strong Sell
Price Target	$35.71